The potential cholestatic effect of amino acids and metabolites of tryptophan were evaluated by use of seven daily intraperitoneal injections to suckling and weanling rat pups. Of the amino acids present in parenteral nutrition solutions, only tryptophan (given at a dose of 4 mM/kg) produced a significant ( p < 0.01) elevation of serum cholylglycine (12.8 2 1.0 pM/liter) as determined by radioimmunoassay, compared to 4.9 f 0.4 pM/liter in salinetreated control animals. Total serum conjugates of cholic acid, as determined by radioimmunoassay, were similarly elevated, as was serum alanine aminotransferase. Tryptophan injection resulted in elevated cholylglycine concentrations only at doses of 3 mM/kg/day or higher. Animals more than 2 weeks old did not demonstrate elevation of serum cholylglycine. Injection of lightexposed tryptophan in suckling animals caused a greater elevation of cholylglycine (39.0 f 8.6 pM/liter) than freshly prepared tryptophan solutions ( p < 0.005). Tryptophan and its spontaneous degradation products could contribute to the cholestatic liver changes observed during parenteral nutrition therapy. Abbreviations ALT, alanine aminotransferase ANIT, a-naphthylisothiocyanate AST, aspartate aminotransferase CCA, conjugates of cholic acid CG, cholylglycine TPN, total parenteral nutrition In 197 1, Peden and coworkers (3 1) reported the occurrence of cholestasis in a premature infant receiving parenteral nutrition. More than 20 subsequent reports have confirmed this observation (2) and have suggested lack ofenteral alimentation (4), sepsis (24). and immature hepatic excretory function (35) as possible etiologies. The incidence of cholestasis is related to the duration of parenteral nutrition (I). The rapidity of onset and the severity has been related to the dose of amino acids administered (36). Such observations suggest that amino acids contained in the solutions may be hepatotoxic.
Summary
The potential cholestatic effect of amino acids and metabolites of tryptophan were evaluated by use of seven daily intraperitoneal injections to suckling and weanling rat pups. Of the amino acids present in parenteral nutrition solutions, only tryptophan (given at a dose of 4 mM/kg) produced a significant ( p < 0.01) elevation of serum cholylglycine (12.8 2 1.0 pM/liter) as determined by radioimmunoassay, compared to 4.9 f 0.4 pM/liter in salinetreated control animals. Total serum conjugates of cholic acid, as determined by radioimmunoassay, were similarly elevated, as was serum alanine aminotransferase. Tryptophan injection resulted in elevated cholylglycine concentrations only at doses of 3 mM/kg/day or higher. Animals more than 2 weeks old did not demonstrate elevation of serum cholylglycine. Injection of lightexposed tryptophan in suckling animals caused a greater elevation of cholylglycine (39.0 f 8.6 pM/liter) than freshly prepared tryptophan solutions ( p < 0.005). Tryptophan and its spontaneous degradation products could contribute to the cholestatic liver changes observed during parenteral nutrition therapy. Abbreviations ALT, alanine aminotransferase ANIT, a-naphthylisothiocyanate AST, aspartate aminotransferase CCA, conjugates of cholic acid CG, cholylglycine TPN, total parenteral nutrition In 197 1, Peden and coworkers (3 1) reported the occurrence of cholestasis in a premature infant receiving parenteral nutrition. More than 20 subsequent reports have confirmed this observation (2) and have suggested lack ofenteral alimentation (4), sepsis (24) . and immature hepatic excretory function (35) as possible etiologies. The incidence of cholestasis is related to the duration of parenteral nutrition (I). The rapidity of onset and the severity has been related to the dose of amino acids administered (36) . Such observations suggest that amino acids contained in the solutions may be hepatotoxic.
Experimental models utilizing perfused rat liver (15, (32) (33) (34) , and isolated rat hepatocytes (7) have demonstrated significant cholestatic effects with both individual amino acids and clinically available amino acid solutions. The present investigation was designed to answer the following questions. 1) Can the cholestatic effect of parenterally administered individual amino acids be demonstrated in the intact neonatal rat? 2) Is the cholestasis a dose-dependent phenomenon? 3) Is there an age-dependent sensitivity to the cholestatic effects of parenteral amino acids in the rats? 4) Is a specific hepatotoxic biologic metabolite of a cholestatic amino acid identifiable?
MATERIALS AND METHODS
Single litters of I -day-old Sprague-Dawley rat pups were randomized to receive intraperitoneal injections of saline alone (control) or one of 14 single amino acids in saline. Leleiko el al. (22) have previously presented evidence for utilization of intraperitoneally administered amino acids. Amino acids studied were the I-forms of tryptophan, valine, histidine, leucine, isoleucine, lysine, threonine, phenylalanine, methionine, arginine, alanine, glycine, serine, and proline (Ajinomoto USA, Inc, Los Angeles). All solutions were freshly prepared and passed through a 0.2-u filter prior to use. Cultures revealed no evidence of bacterial contamination. The various solutions ranged in pH from 5.5 to 7.0. Each experimental animal received a single daily intraperitoneal injection of 4.0 mM/kg of a single amino acid in 0.7 ml. Control animals received 0.7 ml of normal saline solution. The pups were allowed to nurse freely throughout the study, and the mothers were allowed free access to water and Purina rat chow. Individual litters were housed in single cages in a temperaturecontrolled room at 20°C with alternating 12-h light and dark cycles.
After seven days of injections, the pups were fasted for six h starting at 0800 h and exsanguinated by intracardiac puncture following metaphane anesthesia. Serum was obtained for CG concentration, and liver tissue was placed in 10% buffered formalin for light microscopy. Liver specimens for electron microscopy were obtained following metaphane anesthesia and whole body perfusion with 2% glutaraldehyde by left ventricular intracardiac injection following right atrial cardiotomy. In three additional litters given daily injections of either tryptophan (4 mM/kg), leucine (4 mM/kg), or saline, serum was analyzed for total serum conjugates of CCA. In addition, two litters given daily injections of either tryptophan (4 mM/kg) or saline had serum obtained for aminotransferases, alkaline phosphatase, and total bilirubin. Animals from two litters also received the 4 mM/ kg tryptophan or saline injection on the 8th study day at 0800 h and were then fasted until sacrifice at 1400 h for determination of serum glucose.
A dose-response curve for tryptophan was determined by randomizing single litters of 1-day-old rat pups to receive 0 (saline control), 1, 2, 3, or 4 mM/kg of tryptophan as a 0.7-ml daily intraperitoneal injection for 7 days. Doses greater than 4 mM/kg could not be studied because of volume and solubility limitations.
The ability of spontaneously formed and commercially available metabolites of tryptophan to elevate rat serum CG was also evaluated. A tryptophan solution was exposed to roof-top sunlight for 7 days and injected as described above. In addition, freshly prepared doses of 4 mM/kg of commercially available tryptophan metabolites were injected daily for 7 days, except where solubility and injection volume of 0.7 ml dictated a lower dose. The reagents and doses administered (and suppliers) were as follows: kynurenic acid, 4.0 mM/kg; I-kynurenine, 1.3 mM/ kg; anthranilic acid, 2.0 mM/kg; tryptamine hydrochloride, 0.8 mM/kg. 5-hydroxytryptamine, 0.8 mM/kg; I-kynurenine sulfate, 1.3 mM; 3-hydroxyanthranilic acid, 0.8 m M/kg; xanthurenic acid, 3.8 m M/kg; quinolinic acid, 0.8 mM/kg (all from Sigma Chemical Co., St. Louis, MO); 5-hydroxytryptophan, 0.8 mM/ kg (Aldrich Chemical Co., Milwaukee, WI); and N-formyl-lkynurenine, 1.5 mM/kg (Calbiochem, La Jolla, CA). These compounds were used without further purification. After 7 days of injections, the pups were fasted for 6 h and exsanguinated by intracardiac puncture following metaphane anesthesia. Serum was obtained for CG determination.
The effect of age was examined by obtaining serum for CG determination in animals who had received single, daily intraperitoneal injections of 4 mM/kg/kay of tryptophan for 7, 11, and 14 days following birth. In addition, serum CG levels were obtained in 28-day-old rats following 7 days of intraperitoneal saline injections at a dose of 4 mM/kg/d. Results at each age were compared to age-matched saline-injected controls.
There were no significant differences among the various groups in the above studies with regard to weight gain or survival during the study. Overall survival was approximately 90%. Any animal with evidence of peritonitis at the time of sacrifice was eliminated from the study. To confirm the ability of serum CG concentration to rise in response to a known cholestatic agent, 28 weanling (21-day-old) rats were randomized to receive a single 0.5-ml intraperitoneal injection containing either 2.5 mg of ANIT, (Eastman Kodak, Rochester, NY) in corn oil or corn oil alone. The substance is a known potent cholestatic agent in the rat (21) . The animals were sacrificed at 28 and 52 h following injection, and serum was analyzed for CG. Serum CG concentrations (mean + SD) were significantly ( p < 0.0005) elevated in the ANIT-treated group at both 28 and 52 h (100.2 + 20.3 pM/liter and 67.5 & 21.0 pM/liter, respectively) compared to corn oilinjected controls (2.9 + 1.2 pM/liter and 2.8 + 0.5 pM/liter). To determine if elevated concentration of serum tryptophan alters serum cholylglycine values as determined by radioimmunoassay, tryptophan was added in concentrations up to 29 mM to rat serum; less than 10% change in serum CG was observed.
Bile uciu' u'eterminutions. Serum obtained at the time of sacrifice in each experiment was stored at -20°C until the time of analysis. Cholylglycine was determined by a commercially available specific '251-labeled radioimmunoassay (Abbott Diagnostics, North Chicago, IL) (28) . Control sera were run with each radioimmunoassay kit. Samples of 25 p1 of unknown serum or known standards were incubated for 1 h at room temperature with 200 p1 of antiserum. Precipitates were obtained by centrifugation at 4200 x g for 15 min following the addition of 2 ml of 18% (w/v) polyethylene glycol. Samples were counted for 1 min in a Searle Analytic 11-85 Gamma Counter. Results were obtained from log-logit curves produced from standard controls. This method has previously been shown to have excellent direct comparability to gas-liquid chromatography (3) and has the added advantage of a very small sample size. This is a mandatory feature of any serum assay to be used in studies utilizing individual neonatal rat pups. Cross-reactivity with taurine-conjugated cholic acid ranged from 15% (rabbit antibody) to 40% (porcine antibody) for different kit lots. A11 but two of the assays performed (for /-kynurenine and xanthurenic acid) were done with the rabbit antibody.
Total serum conjugates of cholic acid were determined in Dr. William F. Balistreri's laboratory at the Children's Hospital Research Foundation, Cincinnati, OH, by a previously described radioimmunoassay (3). Serum bilirubin, alkaline phosphatase, alanine and aspartate aminotransferases, and glucose were determined by standard laboratory methods (8 
RESULTS
Of the 14 amino acids studied, only tryptophan produced significant elevation of serum CG concentration (Fig. 1) . Tryptophan-treated animals had a mean CG concentration of 12.8 f 3.4 pM/liter compared to 4.9 + 0.9 pM/liter in saline-injected controls ( p < 0.01). When total serum CCA were measured in 8-day-old rat pups that had received 7 days of either tryptophan, leucine, or saline, only the tryptophan group had elevated concentrations. Tryptophan-treated animals had mean total CCA concentrations of 23.3 f 11.2 pM/liter compared to 6.7 + 2.8 pM/liter in leucine-treated animals and 6.5 + 4.2 pM/liter in saline injected controls ( p < 0.005).
A dose-response curve for tryptophan indicated significant elevation of serum CG concentration at doses of 3 mM/kg/day or higher (Fig. 2) . Animals 8 or 12 days old at the time of sacrifice, but not 15-day-old or weanling animals demonstrated elevated CG concentrations following daily intraperitoneal injections of 4 mM/kg/d of tryptophan (Fig 3) . Light and electron microscopy of liver tissue failed to demonstrate consistent differences between tryptophan-and salinetreated animals.
Injection of light-exposed tryptophan in the neonatal rat pups resulted in significantly higher serum CG (39.0 f 8.6 pM/liter) than the injection of non-light-exposed tryptophan (13.5 + 4.8 pM/liter) ( p < 0.0005). None of the specific tryptophan metabolites tested resulted in significant elevation of serum CG in neonatal animals. Although our preliminary experience suggested that kynurenine and anthranilic acid might be cholestatic (27) , daily preparation of fresh solutions of these agents eliminated the apparent cholestatic effect.
DISCUSSION
This study demonstrated elevation of serum CG, a sensitive indicator of cholestasis, when neonatal rats received 3 mM/kg/ day of tryptophan or light-exposed tryptophan by daily intraperitoneal injection. This phenomenon was not apparent at lower doses of tryptophan or in animals 15 days of age or older at the time of sacrifice. Injection neither of other amino acids present in parenteral nutrition solutions nor biologic tryptophan metabolites resulted in significant elevation of CG.
Grant er u1 ( 16) first suggested that tryptophan might be related to the hepatic injury which occurs in some adult patients receiving TPN. In their animal studies, mature rats receiving parenteral nutrition solutions containing freshly added tryptophan showed no abnormalities of liver histology, while animals receiving lightexposed tryptophan exhibited steatosis. Our results indicate greater elevation of serum CG with light-exposed tryptophan.
Hepatic perfusion studies using single amino acids, amino acid analogs, or commercially available amino acid mixtures, have demonstrated decreased bile flow (15, (32) (33) (34) which is dosedependent (15, 32) , possibly related to the composition of the amino acid solution (33) , and largely the result of apparent inhibition of bile acid-independent bile flow (33, 34) . Studies in rabbits receiving TPN have demonstrated a greater reduction in bile flow in infant compared to mature animals (37) . Damage to the canalicular membrane of the hepatocytes of rabbits receiving TPN was also noted. This finding has also been observed in patients with TPN-associated cholestasis ( 10) .
There are interesting parallels between the cholestatic liver disease observed in infants and the results of our studies in neonatal rats. In both situations, the young (premature) are more susceptible, elevation of serum bile acids is one of the earliest detectable changes (12) , and toxicity appears to be dependent upon the dose of amino acids administered. Our observations in neonatal rats given intraperitoneal injections, however, do not approach the clinical complexity of premature newborns receiving parenteral nutrition. The rat pups were allowed to nurse ad DAYS OF AGE (NO. of days of injections) Fig. 3 . Age-dependent effect of tryptophan administration. Daily tryptophan injections were started at 1 day of age and animals sacrificed at 8, 12 . and 15 days of age. The significant elevation of serum CG observed at 8 and 12 days of age was no longer apparent at day 15. V4hrc.s in parenfhese.~, means rt SEM.
lihirzrm; i.e., they were not fasted. Sepsis, which may be a contributing factor in the cholestasis seen in the newborn, was presumably not present. In addition, rapid maturation of the rat pup may prevent the development of chronic liver disease in this species. Hepatotoxicity of a given agent may be extremely species-specific, and animal studies may not be directly applicable to human clinical situations.
The ontogeny of activity of tryptophan oxygenase (EC 1.13.1 1.1 1) the initial hepatic enzyme in the tryptophan catabolic pathway has been studied in rat pups (17) . As adrenalectomy diminishes the late suckling increase in tryptophan oxygenase, and low tryptophan oxygenase activity might be related to susceptibility of neonatal animals to tryptophan-induced cholestasis, we performed adrenalectomies in a group of rat pups at 3 days of age. Tryptophan injections (4 mM/kg) were continued through day 20 and the animals were sacrificed on day 21. No differences were noted in the CG concentrations of adrenalectomized verszrs nonoperated animals.
The single doses of tryptophan employed in our studies are beyond the usual physiologic daily intake. The daily tryptophan intake of the nursed rat can be estimated at approximately 0.37 mM/kg/day (calculated from Ref. 6 ). Our usual study dose adds 4 mM/kg/day, assuming that the entire dose remains within the peritoneal cavity and is absorbed. Breast-fed human neonates receive approxiamtely 0.12 mM/kg/day of tryptophan (calculated from Ref. 13 ). Neonates receiving 140 ml/kg/day of a 2% amino acid solution daily receive 0.21 mM/kg/day of tryptophan.
Tryptophan is an amino acid with a number of unique qualities. It is the essential amino acid required in least quantity, it circulates partially bound to albumin in the blood (23) , and it can inhibit gluconeogenesis. In addition, tryptophan can affect electrolyte and water absorption from the intestinal lumen (9, 25). 5-OH-Tryptamine, a tryptophan metabolite, alters tone of the sphincter of Oddi (2). It is possible that tryptophan may alter bile acid excretion by virtue of its effects on water and mineral transport or as a precursor for 5-OH-tryptamine and its effect on bile duct motility. These possibilities have not been tested directly.
Of special note is tryptophan's sensitivity to degradation on exposure to light. Tryptophan in solutions used for intravenous nutrition has been noted to spontaneously degrade (19, 20, 29) . Intensive light exposure, particularly in the presence of riboflavin. appears to hasten this process (5) . Clear tryptophan solutions exposed to bright sunlight or ultraviolet light for a few hours turn brown in color. This browning is probably not due to the Millard reaction, as has been noted in amino acid-dextrose solutions that were heat sterilized, as dextrose was not added to our solutions. Other types of tryptophan degradation products have been previously noted. The brown compounds resulting from photo-oxidation may be related to the enhanced cholestatic effect.
Recent work has demonstrated altered bile composition in TPN patients who developed evidence of hepatotoxicity (14) . Increased secondary bile acids, most notably lithocholic acid, have been found. Our study suggests that a preformed component in light-exposed, tryptophan-containing solutions alters bile acid metabolism or excretion. If a component of TPN solution led to increased lithocholic acid formation, lithocholic acid could produce the type of liver injury seen in TPN-associated cholestasis (30) . especially in the absence of taurine intake (1 I). Further in virro, in vivo, and clinical studies will be required to evaluate this hypothesis.
SUMMARY
Of the amino acids present in parenteral nutrition solutions, only tryptophan was found to elevate the serum cholylglycine concentrations when injected intraperitoneally into suckling rat pups daily for 7 days. Light-exposed tryptophan was more cholestatic than freshly prepared tryptophan.
